Trial Profile
16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Nasal polyps
- Focus Therapeutic Use
- Sponsors OptiNose
- 22 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Mar 2026.
- 22 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Mar 2026.
- 22 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.